PT - JOURNAL ARTICLE AU - Seki, Yohei AU - Yoshihara, Yasuo AU - Nojima, Kiyoko AU - Momose, Haruka AU - Fukushi, Shuetsu AU - Moriyama, Saya AU - Wagatsuma, Ayumi AU - Numata, Narumi AU - Sasaki, Kyohei AU - Kuzuoka, Tomoyo AU - Yato, Yoshiyuki AU - Takahashi, Yoshimasa AU - Maeda, Ken AU - Suzuki, Tadaki AU - Mizukami, Takuo AU - Hamaguchi, Isao TI - Safety and immunogenicity of Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine against SARS-CoV-2 Omicron variant in Japanese healthcare workers AID - 10.1101/2022.01.20.22269587 DP - 2022 Jan 01 TA - medRxiv PG - 2022.01.20.22269587 4099 - http://medrxiv.org/content/early/2022/01/21/2022.01.20.22269587.short 4100 - http://medrxiv.org/content/early/2022/01/21/2022.01.20.22269587.full AB - Background The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified in Japan in November 2021. This variant contains up to 36 mutations in the spike protein, the target of neutralizing antibodies, and can escape vaccine-induced immunity. The third booster vaccination campaign began with healthcare workers and high-risk groups. The safety and immunogenicity of third booster vaccination against Omicrons remain unknown.Methods In total, 272 healthcare workers were evaluated for their long-term safety and immunogenicity. Here, we established vaccine panels to evaluate the safety and immunogenicity against variants of concern (VOCs), including the Omicron variant, using a live virus microneutralization assay.Findings Two-dose vaccination induced robust anti-spike antibodies and neutralization titers (NTs) against the ancestral strain WK-521, whereas NTs in VOCs were significantly decreased. Within 93–247 days of the second vaccine dose, NTs against Omicron were completely abolished in up to 80% of individuals among the vaccine panels. The third booster vaccination induced a robust increase in anti-spike antibodies and NTs against the WK-521, Delta, and Omicron variants. The breadth of humoral immunity and cross-reactivity with Omicron increased. The cytokine signature and adverse event rate remained unchanged after three-dose vaccination.Conclusions The third vaccination dose is safe and effective against Omicron infection.Funding This study was supported by grants from AMED (Grant Number JP21fk0108104 and JP21mk0102146).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by grants from AMED (Grant Number JP21fk0108104 and JP21mk0102146).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Medical research ethics committee of the National Institute of Infectious Diseases (NIID) and Murayama Medical center, National Hospital Organization.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.